BriaCell’s most recent Phase 2 study cohort of 25 patients* achieved a 52% one-year survival rate (i.e. 52% of patients remained alive at least one year after starting on the study). 11 of these ...

Alignment serves approximately 217,500 Medicare beneficiaries in five states: Arizona, California, Nevada, North Carolina and Texas. It has been recognized with a range of accolades, including earning ...

Laru-zova is investigational and has not been approved by FDA for use.

As previously announced, iCAD entered into a definitive merger agreement under which RadNet will acquire iCAD in an all-stock transaction. The acquisition is structured to accelerate the deployment of ...

In addition, after receiving a delisting notice from Nasdaq, Vaxart has requested a hearing before a Nasdaq Hearings Panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.

The ReSPECT-LM dose optimization trial benefits from a $17.6 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT), the second largest public funding source for cancer ...

Abstract Title: First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome Poster Viewing Date & Time: September 13, 2025, 3:30 - 4:00 p.m. local time & Welcome Reception Poster Topic: ...

SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies ...

Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and quality ...

Medvantx will offer a combined solution set with additional capabilities leveraging RxS’s advanced sampling, engagement, and technology-driven compliance tools. It will offer: Multichannel sample ...

Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the ...

Symvess (acellular tissue engineered vessel-tyod) was approved in the extremity vascular trauma indication by the Food and Drug Administration (FDA) in December 2024.